Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 15921 - 15940 out of 553704 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Australia | (L01FF05) atezolizumab (adm: P) | Tecentriq SC 1.875 g/15 mL injection, 15 mL vial | Solution for subcutaneous injection 1875 mg in 15 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheProductsPtyLtd |
| Australia | (L01FF05) atezolizumab (adm: P) | Tecentriq SC 1.875 g/15 mL injection, 15 mL vial | Solution for subcutaneous injection 1875 mg in 15 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheProductsPtyLtd |
| Australia | (L01FF05) atezolizumab (adm: P) | Tecentriq SC 1.875 g/15 mL injection, 15 mL vial | Solution for subcutaneous injection 1875 mg in 15 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheProductsPtyLtd |
| Australia | (L01FF05) atezolizumab (adm: P) | Tecentriq SC 1.875 g/15 mL injection, 15 mL vial | Solution for subcutaneous injection 1875 mg in 15 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheProductsPtyLtd |
| Australia | (L01FF05) atezolizumab (adm: P) | Tecentriq SC 1.875 g/15 mL injection, 15 mL vial | Solution for subcutaneous injection 1875 mg in 15 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheProductsPtyLtd |
| Australia | (L01FX04) ipilimumab (adm: P) | Yervoy 50 mg/10 mL injection, 10 mL vial | Injection concentrate for I.V. infusion 50 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FX04) ipilimumab (adm: P) | Yervoy 50 mg/10 mL injection, 10 mL vial | Injection concentrate for I.V. infusion 50 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FX04) ipilimumab (adm: P) | Yervoy 50 mg/10 mL injection, 10 mL vial | Injection concentrate for I.V. infusion 50 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FX04) ipilimumab (adm: P) | Yervoy 50 mg/10 mL injection, 10 mL vial | Injection concentrate for I.V. infusion 50 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FX04) ipilimumab (adm: P) | Yervoy 50 mg/10 mL injection, 10 mL vial | Injection concentrate for I.V. infusion 50 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FX04) ipilimumab (adm: P) | Yervoy 50 mg/10 mL injection, 10 mL vial | Injection concentrate for I.V. infusion 50 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FX07) blinatumomab (adm: P) | Blincyto (1 x Blincyto vial, 1 x Blincyto IV Stabiliser vial), 1 pack | Powder for I.V. infusion 38.5 micrograms, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | AmgenAustraliaPtyLimited |
| Australia | (L01FX07) blinatumomab (adm: P) | Blincyto (1 x Blincyto vial, 1 x Blincyto IV Stabiliser vial), 1 pack | Powder for I.V. infusion 38.5 micrograms, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | AmgenAustraliaPtyLimited |
| Australia | (L01FX27) epcoritamab | Epkinly 4 mg/0.8 mL injection, 0.8 mL vial | Solution concentrate for subcutaneous injection 4 mg in 0.8 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse | AbbViePtyLtd |
| Australia | (L01FX27) epcoritamab | Epkinly 48 mg/0.8 mL injection, 0.8 mL vial | Solution for subcutaneous injection 48 mg in 0.8 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse | AbbViePtyLtd |
| Australia | (L01FX27) epcoritamab | Epkinly 48 mg/0.8 mL injection, 0.8 mL vial | Solution for subcutaneous injection 48 mg in 0.8 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse | AbbViePtyLtd |
| Australia | (L01XX66) selinexor | Xpovio 20 mg tablet, 16 | Tablet 20 mg, 16 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | ANTENGENE(AUS)PTY.LTD. |
| Australia | (L01XX66) selinexor | Xpovio 20 mg tablet, 20 | Tablet 20 mg, 20 pcs | Wholesale price without vat |
$0-0 |
$0-0 |
n/a | ANTENGENE(AUS)PTY.LTD. |
| Australia | (L01XX66) selinexor | Xpovio 20 mg tablet, 32 | Tablet 20 mg, 32 pcs | Wholesale price without vat |
$0-0 |
$0-0 |
n/a | ANTENGENE(AUS)PTY.LTD. |
| Australia | (L01XX79) eflornithine | Ifinwil 192 mg tablet, 100 | Tablet 192 mg (as hydrochloride), 100 pcs | Retail price without vat |
$0-0 |
$0-0 |
n/a | NorginePty.Ltd. |
Pages
